KDR and neoplasm: Anlotinib is a small-molecule multitarget tyrosine kinase inhibitor that can effectively inhibit VEGFR, PDGFR, FGFR, c-Kit, and other kinases and that has antitumor angiogenic effects and can inhibit tumor growth.